ReviewJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi2022
Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures.
Review in Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Performance of artificial intelligence in predicting the prognossis of severe COVID-19: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Long-term trajectories of reproductive and pituitary-adrenal-thyroid hormones in young males following Omicron BA.2 infection: a two-year prospective cohort study.Frontiers in endocrinology · 2026Article
- Dynamic alterations of oral fungal microbiota in Omicron infected patients.Scientific reports · 2025Article
- Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.Current pharmaceutical design · 2025Review
- Incidence of severe and non-severe SARS-CoV-2 infections in children and adolescents: a population-based cohort study using six healthcare databases from Italy, Spain, and Norway.European journal of pediatrics · 2024Article
- Article
- Vertical transmission of SARS-CoV-2 delta-variant in a preterm infant.BMC infectious diseases · 2024Article
- Dynamic changes of Bacterial Microbiomes in Oropharynx during Infection and Recovery of COVID-19 Omicron Variant.PLoS pathogens · 2024Article
- The Influence of HLA Polymorphisms on the Severity of COVID-19 in the Romanian Population.International journal of molecular sciences · 2024Article
- Association of IFNAR2 and TYK2 with COVID-19 pathology: current and future.Frontiers in immunology · 2024Article
- Performance evaluation of the cobas SARS-CoV-2 Duo, a novel qualitative and quantitative assay, for the detection of SARS-CoV-2 RNA.Microbiology spectrum · 2023Article
- Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Effectiveness of COVID-19 vaccines against ICU admission during Omicron surge in Saudi Arabia: a nationwide retrospective cohort study.BMC infectious diseases · 2023Article
- Factors associated with COVID-19 vaccination coverage in hypertensive patients with Omicron infection in Shanghai, China.Human vaccines & immunotherapeutics · 2023Article
- SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx.Cell reports. Physical science · 2023Article
- Effects of Chinese provincial CDCs WeChat official account article features on user engagement during the COVID-19 pandemic.Journal of global health · 2023Article
- Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.Journal of medical virology · 2023Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Omicron (B.1.1.529) variant was first reported in South Africa and rapidly spread worldwide in early November 2021. This caused panic in various countries, so it is necessary to understand Omicron Variant. This paper summarizes omicron variant-related research achievements. Studies have shown that Omicron Variant contains many mutations that make it more infectious and transmissible. At the same time, immune escape is also caused, resulting in reduced efficacy of existing vaccines, increased risk of reinfection, treatment failure or reduction of monoclonal antibody therapies, and detection failure. However, current data indicate that Omicron Variant causes mild clinical symptoms and few severe cases and deaths. Omicron Variant is valid for a range of nonpharmaceutical interventions against SARS-CoV-2. Improving diagnostic accuracy and enabling timely isolation and treatment of diagnosed cases is also critical to interrupting the spread of omicron variants. COVID-19 vaccine boosters could undoubtedly help control Omicron spread and infection. However, developing a vaccine specific to Omicron Variant is also imminent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.